These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34583363)

  • 41. Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina.
    Demir N; Sevincli S; Kayhan B; Sonmez M
    Cutan Ocul Toxicol; 2021 Jun; 40(2):135-139. PubMed ID: 33944638
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.
    Yamashiro K; Oishi A; Hata M; Takahashi A; Tsujikawa A
    Jpn J Ophthalmol; 2021 Nov; 65(6):741-760. PubMed ID: 34491474
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of intravitreal injections of Ranibizumab and Aflibercept in neovascular age related macular degeneration.
    Sizmaz S; Esen E; Isik-Ericek P; Demircan N
    Clin Exp Optom; 2022 Jan; 105(1):55-60. PubMed ID: 33719869
    [No Abstract]   [Full Text] [Related]  

  • 44. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
    Fauser S; Viebahn U; Muether PS
    Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
    Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
    JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
    Bro T; Hägg S
    Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systematic review and meta-analysis.
    Fallico M; Lotery AJ; Longo A; Avitabile T; Bonfiglio V; Russo A; Castellino N; Parisi G; Pulvirenti A; Eandi C; Cennamo G; Furino C; Cicinelli MV; Alovisi C; Reibaldi M
    Eur J Ophthalmol; 2021 Sep; 31(5):2496-2504. PubMed ID: 33118382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in Serum Concentrations of Vascular Endothelial Growth Factors-A and B after Intravitreal Injection of Ranibizumab and Conbercept for Retinopathy of Prematurity.
    Zhang H; Yang X; Zheng F; Wan S; Xu Y
    Ophthalmologica; 2023; 246(2):81-89. PubMed ID: 36709750
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
    Kaya F
    J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
    Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G
    Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a Meta-analysis and systematic review.
    Liu WS; Li YJ
    Int J Ophthalmol; 2019; 12(9):1479-1486. PubMed ID: 31544046
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of different agents, dosages and strategies of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials.
    Zhao XY; Meng LH; Liu SZ; Chen YX
    Acta Ophthalmol; 2021 Nov; 99(7):e1041-e1050. PubMed ID: 33438364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-minimization Analysis of Ranibizumab versus Aflibercept in the Treatment of Neovascular Age-related Macular Degeneration in Colombia.
    Sánchez-Thorin JC
    Ophthalmic Epidemiol; 2020 Dec; 27(6):482-486. PubMed ID: 32715820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma.
    Guo X; Wang Y; Yang L; Wang P; Chen K; Zhou L; Wu Y
    Int Ophthalmol; 2021 Aug; 41(8):2869-2877. PubMed ID: 33895882
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Holz FG; Oleksy P; Ricci F; Kaiser PK; Kiefer J; Schmitz-Valckenberg S;
    Ophthalmology; 2022 Jan; 129(1):54-63. PubMed ID: 33957183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Huang Z; Ding Q; Yan M; Lian H; Chen Z; Chen X; Song Y
    Retina; 2019 May; 39(5):889-895. PubMed ID: 29360683
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
    Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
    Mitchell P
    Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.